Curia Puts USD 28 Million into Spanish Sterile API: 'Sterile + High-Potency' Is the Quiet Capex Mainline of Western CDMOs

US CDMO giant Curia announced on 27 October a USD 28 million expansion of sterile API manufacturing at its Valladolid, Spain site, completing in Q4 2028 with new steroid and non-steroid capabilities and integrated aseptic crystallisation, milling and micronisation. The investment follows a USD 4 million aseptic-suite upgrade in May and a USD 200 million sterile drug-product expansion in New Mexico. While the industry's attention is fixed on biologics litres and peptide tonnes, Western CDMOs' capex is quietly converging on 'sterile + high-potency + complex formulations'.

Curia Global, headquartered in Albany, New York, announced on 27 October a USD 28 million investment to expand sterile active pharmaceutical ingredient (API) manufacturing at its Valladolid, Spain site, with completion expected in the fourth quarter of 2028. The expansion adds steroid and non-steroid API capabilities, combining sterile manufacturing with aseptic crystallisation, milling and micronisation to support injectable suspensions and other complex sterile formulations. Closed systems with barrier isolators provide primary containment during sterile API handling, capacity spans gram-scale to metric tons, and customisable aseptic packaging reduces contamination risk during transfers and storage.

A string of moves: sterile is the through-line

This is no isolated bet. The Valladolid site completed a USD 4 million API aseptic-suite upgrade in May; before that, Curia finished a USD 200 million sterile drug-product expansion in Albuquerque, New Mexico, adding 70,000 square feet and two isolated filling lines for syringes, cartridges and vials, plus lyophilisation and packaging. In September, synthetic-biology company eXoZymes selected Curia to transfer and scale its enzymatic production of N-trans-caffeoyltyramine at sites in Leon, Spain and Rozzano, Italy, with scale-up validation starting in Q4 2026 and commercial production targeted for Q3-Q4 2027. From sterile API to sterile drug product to biomanufacturing, 'sterile' is the recurring qualifier on Curia's capex list.

Why sterile API deserves its own look

Sterile API is the most overlooked bottleneck in injectable supply chains: the API synthesis tail must enter a sterile environment while crystallisation, milling and micronisation remain compatible with aseptic barriers, and few sites worldwide cover the full gram-to-ton range. Steroid high-potency APIs raise the bar further — long synthesis routes, tight impurity control and strict occupational-exposure limits keep global supply concentrated in a handful of bases. With high-value injectables scaling and Section 232 tariffs reshaping site selection, Western sterile API and complex-formulation capacity is becoming a scarce asset — which also explains why a European site (eligible for the EU's preferential 15% tariff rate) carries origin value for customers selling into the US market.

The China contrast: same bottleneck, different solutions

The comparison is instructive. China's leading CXOs solve 'high-potency + complex formulations' through vertical integration: WuXi XDC links payload-linker, drug substance and drug product end-to-end for ADCs; Asymchem's payload-linker capacity is 'very tight' and expanding fast; Haoyuan Pharma just broke ground on Phase II of its Chongqing ADC campus. Curia represents the other path — Western mid-to-large CDMOs making horizontal capex along a 'sterile + high-potency' axis, combining multiple sites to carry the same order types. Both routes point to the same conclusion: in the injectable era, sterile capability is shifting from 'nice to have' to 'entry ticket'.

Editor's note: the capex list is more honest than the press release

If you want to read a CDMO's strategy, its capacity announcements are more honest than its vision statements. Curia's last twelve months — USD 28 million sterile API, USD 4 million aseptic suites, USD 200 million sterile drug product with lyophilisation, eXoZymes biomanufacturing scale-up — contain not a single project for conventional oral solid dosage or legacy fermentation. While the peptide and biologics litre race absorbs nearly all the attention, sterile API and complex sterile formulations may be the quiet mainline that decides pricing power in injectable supply chains. For procurement teams, add it to the diligence list: sterile capacity in the next decade may be harder to find than bioreactor litres.